Sterility Testing of Injectable Preparations: Methods, Standards, and Regulatory Requirements

Sterility testing of injectable preparations is a mandatory microbiological quality control test that verifies the absence of viable bacteria and fungi in parenteral products prior to batch release. Performed in accordance with pharmacopoeial standards such as the Chinese Pharmacopoeia (ChP), USP, Ph. Eur., and ISO 11737-2, this test is a fundamental safeguard for patient safety. This article provides a comprehensive technical overview of injectable sterility testing, covering sample types, test media, methodology, incubation parameters, result interpretation, and regulatory requirements.

Technical Overview

Sterility testing is a compendial microbiological assay designed to detect the presence of viable microorganisms, including aerobic bacteria, anaerobic bacteria, yeasts, and molds, in pharmaceutical products labeled as sterile. For injectable preparations, sterility is a critical quality attribute: because parenteral administration bypasses the body's natural defense barriers such as skin and mucous membranes, microbial contamination in an injection can lead directly to bacteremia, septicemia, pyrogenic reactions, endotoxin shock, or death. Sterility testing therefore serves as the final microbiological verification step before a sterile injectable product is released to the market.

The test is governed by harmonized pharmacopoeial chapters, principally the Chinese Pharmacopoeia General Chapter 1101 (Sterility Test), USP General Chapter <71>, Ph. Eur. Section 2.6.1, and JP 4.06. Supporting standards include ISO 11737-2 for microbiological test methods related to sterilization processes and ISO 14644-1 for cleanroom classification. Because the sterility test is destructive and probability-based, it supplements—rather than replaces—a robust sterility assurance system built on validated sterilization processes, aseptic processing controls, and current Good Manufacturing Practice (GMP).

• Detects viable aerobic bacteria, anaerobic bacteria, and fungi in sterile injectable products
• Requires performance under aseptic conditions in a Grade A (ISO Class 5) environment with an appropriate Grade B background, or in a validated isolator
• Requires a validated method suitability test (bacteriostasis and fungistasis test) to confirm the product does not inhibit microbial growth
• Involves a minimum 14-day incubation period with two culture media before a final result can be issued

Testing Samples

Small Volume Parenteral Solutions

Aqueous solutions in ampoules or vials of up to 100 mL, including solutions for intramuscular, intravenous, subcutaneous, and intrathecal administration. These products are typically tested by membrane filtration after pooling the contents of the required number of containers. Where the volume is insufficient, the entire contents of each container are filtered and the membrane is divided between the two media.

Large Volume Parenterals and Infusions

Intravenous infusion solutions exceeding 100 mL, such as electrolyte solutions, carbohydrate infusions, and dialysis solutions. The large fill volume makes membrane filtration the preferred method, and the rinse volume must be sufficient to eliminate any residual antimicrobial or preservative activity from the membrane surface.

Powders for Injection

Sterile crystalline powders and lyophilized (freeze-dried) powders intended for reconstitution before administration. The contents of the required containers are dissolved in a suitable sterile diluent, such as 0.1% peptone water or the product's reconstitution diluent, and the resulting solution is tested by membrane filtration.

Suspensions, Emulsions, and Oily Injections

Products that cannot be filtered through a 0.45 µm membrane, including oily solutions, fat emulsions, and antibiotic suspensions. These are generally tested by the direct inoculation method, with appropriate dilution to reduce antimicrobial activity and ensure the product does not exceed a growth-inhibitory proportion of the culture medium.

Pre-filled Syringes, Cartridges, and Biological Products

Sterile products in pre-filled delivery systems, as well as vaccines, monoclonal antibodies, blood products, and other biologics. Biologics with inherent antimicrobial or preservative properties require particular attention during method suitability testing, and preservatives such as benzalkonium chloride or parabens must be effectively neutralized during filtration and rinsing.

Testing Items

The core deliverable of the test is a compliance determination of sterility against the acceptance criterion of no detectable viable microorganisms. To support this determination, an accredited third-party laboratory typically executes the following items:

• Sterility test for aerobic and anaerobic bacteria using Fluid Thioglycollate Medium (FTM), incubated at 30–35 °C for not fewer than 14 days
• Sterility test for aerobic bacteria and fungi (yeasts and molds) using Soybean-Casein Digest Medium (SCDM/Tryptic Soy Broth), incubated at 20–25 °C for not fewer than 14 days
• Method suitability validation (bacteriostasis and fungistasis testing) using the six standard reference strains: Staphylococcus aureus, Pseudomonas aeruginosa, Bacillus subtilis, Clostridium sporogenes, Candida albicans, and Aspergillus brasiliensis
• Growth promotion testing of each lot of culture medium to confirm its nutritive properties
• Environmental monitoring of the test area, including viable air sampling, settle plates, and surface monitoring, in accordance with ISO 14644 and GMP requirements
• Identification of any recovered microorganisms to the species level in the event of growth, to support contamination source investigation

Testing Methods

Membrane Filtration Method

Membrane filtration is the preferred compendial method whenever the product is aqueous, soluble, or otherwise filterable. The specified quantity of product is filtered aseptically through a sterile membrane with a nominal pore size of 0.45 µm, which retains any viable microorganisms on the membrane surface. The membrane is then rinsed with one or more volumes of a sterile rinsing fluid, commonly 0.1% peptone water with or without neutralizers, to remove residual antimicrobial substances. The membrane is aseptically transferred to containers of FTM and SCDM (or the medium is introduced into the filtration canister) and incubated. This method offers high sensitivity and is effective for products containing preservatives because the rinse step physically removes inhibitory agents.

Direct Inoculation Method

Direct inoculation is used for products that cannot be filtered, such as oily injections, viscous suspensions, and certain biological preparations. A measured quantity of the product is transferred directly into vessels containing the two culture media, taking care that the volume of product does not exceed 10% of the medium volume unless equivalence is demonstrated, so that the growth-promoting properties of the medium are not compromised. The vessels are then incubated under the standard conditions. This method is simpler but less effective at overcoming antimicrobial activity, which makes suitability testing particularly important.

Method Suitability Testing

Before the sterility test can be applied to a product, it must be demonstrated that the product itself does not inhibit the growth of the test organisms. Each medium is inoculated with fewer than 100 colony-forming units of the relevant reference strains, both in the presence of the product (using the proposed test conditions) and in a positive control without product. Growth in the product-containing vessels comparable to the controls within five days (seven days for molds) confirms suitability. If inhibition is observed, corrective measures include increasing the rinse volume, adding specific neutralizers such as lecithin or polysorbate 80, replacing the membrane type, or diluting the product.

Incubation, Observation, and Interpretation

Inoculated media are incubated for not fewer than 14 days: FTM at 30–35 °C and SCDM at 20–25 °C. The vessels are examined visually at defined intervals, for example on days 3 or 4, day 7, and day 14, or daily where required, for evidence of microbial growth such as turbidity. If no visible growth is observed by the end of the incubation period, the product complies with the test for sterility. If growth is observed, the result triggers a formal out-of-specification investigation covering laboratory error, environmental monitoring data, and manufacturing records; a retest is only permissible under strictly defined conditions, such as documented evidence of a laboratory or test-related error. Any isolate must be identified and its significance evaluated as part of the investigation.

Applications

Sterility testing of injectable preparations is applied across the entire product lifecycle and is a regulatory expectation for virtually all parenteral products. Typical applications include:

• Batch release testing of commercial lots of injections, infusions, powders for injection, and pre-filled syringes prior to distribution
• Registration and market authorization dossiers submitted to regulatory authorities, where complete sterility test data and method validation are required
• Validation and periodic requalification of sterilization processes, including support for aseptic process simulation programs
• Long-term and accelerated stability studies, where sterility is verified at defined time points throughout the product shelf life
• Import testing and post-market surveillance of parenteral products
• Hospital pharmacy preparations such as total parenteral nutrition admixtures and extemporaneously compounded sterile injectables

FAQ

How long does a sterility test take?

The compendial incubation period is not fewer than 14 days for both media. Including sample preparation, method suitability confirmation, and reporting, a complete sterility test for an injectable preparation typically requires two to three weeks from receipt of the sample. If the direct inoculation method is used for certain products, incubation and observation schedules specified in the applicable pharmacopoeia must be followed.

How is the sampling plan for a batch determined?

The number of containers tested depends on the batch size, following the tables in USP <71>, ChP 1101, and Ph. Eur. 2.6.1. As a general rule, batches of up to 100 containers require 10% of the batch or 4 containers, whichever is greater; batches of 100 to 500 containers require 10 containers; and larger batches require 2% of the batch or 20 containers, whichever is less. The volume tested per container is also specified according to the product presentation.

What is the difference between sterility testing, bioburden testing, and bacterial endotoxin testing?

Sterility testing detects viable microorganisms in a finished sterile product and yields a presence-or-absence result. Bioburden testing quantifies the total microbial load on or in a product before sterilization and is used to validate sterilization cycles. Bacterial endotoxin testing (LAL test) detects endotoxins from Gram-negative bacterial cell walls and is a separate, complementary requirement for injectable products. All three tests are typically required as part of a complete microbiological quality control program.

Why is the test performed in a Grade A / ISO Class 5 environment?

The test manipulates sterile product in open or exposed conditions, so any environmental microorganism introduced during testing would cause a false positive. The test is therefore performed in a unidirectional airflow cabinet or isolator located in a classified cleanroom area, with comprehensive environmental monitoring to demonstrate that the test environment did not contribute to any observed contamination, in line with GMP and ISO 14644 requirements.

Can a failed sterility test be repeated?

A retest is only justified when the investigation provides documented evidence that the original result was due to a laboratory or method-related error, such as invalid environmental monitoring data or a confirmed error in test execution. If the investigation identifies no assignable cause, or if the contamination is traced to the product or manufacturing process, the batch must be rejected. Regulatory guidance strictly limits retesting to prevent masking of genuine product contamination.